Wrays is delighted to announce the appointment of Grant Shoebridge to the Sydney Life Sciences Team. Grant is widely regarded as one of Australia’s leading patent attorneys with specialist expertise in the fields of molecular and cell biology, immunology, pharmaceuticals, cell and gene therapy, medical devices and diagnostic technology.
Grant has extensive experience running patent oppositions including responsibility for five concurrent patent oppositions making up the Australian component of the CRISPR gene editing global litigation. He also has a proven track record securing extensions of term on pharmaceutical patents and is a recognised authority on gene-related patentable subject matter in both Australia and the US.
Prior to entering the patent profession, Grant enjoyed a 15-year career in medical research, that included a PhD directed to antibody engineering and immunoglobulin polyreactivity. He has also engaged in breast cancer research, DNA vaccine development, as well as working for biotech start-ups in London, Switzerland and Sydney.
Grant said of his appointment “I am excited to be joining Wrays’ Sydney team. Wrays is renowned for its outstanding expertise in acting for pharmaceutical and biotechnology companies and this dovetails into my experience. I want to thank Gary and Todd for this opportunity and look forward to contributing to the success of the Firm.”
Todd Shand, the leader of the Wrays Life Sciences team, welcomed Grant saying “Grant brings a wealth of knowledge in the area of life sciences and will bolster our team’s expertise in the area of immunology and antibody engineering. Most importantly, Grant is a great cultural fit for Wrays and I am really looking forward to having him as part of our team.”
Connect with Grant on LinkedIn or via email grant.shoebridge@wrays.com.au
We formally welcome Grant to Wrays.